Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Alpha Tau Medical Ltd. Warrant (DRTSW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: DRTSW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -51.92% | Avg. Invested days 17 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.99 | 52 Weeks Range 0.09 - 0.50 | Updated Date 06/6/2025 |
52 Weeks Range 0.09 - 0.50 | Updated Date 06/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -25.17% | Return on Equity (TTM) -47.95% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 47275829 |
Shares Outstanding - | Shares Floating 47275829 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Alpha Tau Medical Ltd. Warrant
Company Overview
History and Background
Alpha Tau Medical Ltd. is an Israeli medical device company founded in 2009. It focuses on developing and commercializing the Alpha DaRT technology for treating solid tumors. The warrants offer the holder the right to purchase shares of Alpha Tau Medical Ltd. stock at a specified price within a specified time.
Core Business Areas
- Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy): Alpha DaRT is the core technology, designed for the treatment of solid tumors. It involves the intratumoral insertion of radioactive seeds to deliver targeted alpha radiation.
Leadership and Structure
The leadership team comprises experienced professionals in medical device development, commercialization, and regulatory affairs. The organizational structure is typical for a small-cap medical device company.
Top Products and Market Share
Key Offerings
- Alpha DaRT: Alpha DaRT is the primary offering. While specific market share data is still emerging, it targets a segment of the radiation oncology market. Competition includes established radiation therapy techniques (external beam radiation, brachytherapy) and emerging targeted therapies. Revenue is still growing as more clinical trial data is published and the product sees wider use
Market Dynamics
Industry Overview
The radiation oncology market is characterized by technological advancements (e.g., proton therapy, stereotactic body radiation therapy) and a growing focus on personalized medicine. There is increasing demand for therapies with improved efficacy and reduced side effects.
Positioning
Alpha Tau Medical Ltd. aims to differentiate itself with its targeted alpha radiation therapy, potentially offering a more precise and effective treatment option for certain solid tumors. The warrant is tied to the common stock performance.
Total Addressable Market (TAM)
The total addressable market for solid tumor therapies is substantial, estimated in the billions of dollars annually. Alpha Tau Medical Ltd. aims to capture a segment of this market by offering a novel radiation therapy option.
Upturn SWOT Analysis
Strengths
- Novel technology (Alpha DaRT)
- Targeted therapy with potential for improved efficacy
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Limited commercialization history
- Reliance on clinical trial data for market adoption
- Competition from established radiation therapy techniques
- Need for significant capital investment for expansion
Opportunities
- Expanding clinical applications of Alpha DaRT
- Partnerships with leading oncology centers
- Regulatory approvals in key markets
- Development of new Alpha DaRT delivery systems
Threats
- Competition from established radiation therapy techniques
- Regulatory hurdles
- Reimbursement challenges
- Clinical trial failures
Competitors and Market Share
Key Competitors
- VAR
- EBS
- ISRG
Competitive Landscape
Alpha Tau is disruptive in radiation therapy by delivering alpha emitters intratumorally. Alpha Tau's advantage lies in potentially superior tumor cell killing with minimal damage to healthy tissue but it requires expertise to adopt.
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily linked to clinical trials and is dependent on the success and publication of the trials.
Future Projections: Future growth depends on regulatory approvals and commercialization efforts. Analyst estimates are speculative at this point.
Recent Initiatives: Recent initiatives include expansion of clinical trials, partnerships with cancer centers, and regulatory submissions.
Summary
Alpha Tau Medical is a high-risk, high-reward company with a disruptive approach to cancer treatment. Its success hinges on positive clinical trial outcomes, regulatory approvals, and successful commercialization. Investors need to consider the risks associated with small-cap biotech companies, including funding risks and competition. The warrant's value is directly tied to Alpha Tau's stock performance and conversion options.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Clinical trial data
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Invest at your own risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alpha Tau Medical Ltd. Warrant
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-03-08 | CEO & Chairman Mr. Uzi Sofer | ||
Sector Healthcare | Industry Biotechnology | Full time employees 125 | Website https://www.alphatau.com |
Full time employees 125 | Website https://www.alphatau.com | ||
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical or pending clinical studies for brain and other cancers. The company is headquartered in Jerusalem, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.